Aspen Pharmacare Holdings Ltd

JSE:APN South Africa Drug Manufacturers - Specialty & Generic
Market Cap
$3.13 Billion
ZAC5.89 Trillion ZAC
Market Cap Rank
#24076 Global
#24 in South Africa
Share Price
ZAC13259.00
Change (1 day)
+0.74%
52-Week Range
ZAC9100.00 - ZAC18126.00
All Time High
ZAC34515.40
Categories
Companies in South Africa Drug Manufacturers - Specialty & Generic
About

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic ag… Read more

Aspen Pharmacare Holdings Ltd (APN) - Net Assets

Latest net assets as of June 2025: ZAC84.89 Billion ZAC

Based on the latest financial reports, Aspen Pharmacare Holdings Ltd (APN) has net assets worth ZAC84.89 Billion ZAC as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ZAC135.89 Billion) and total liabilities (ZAC51.00 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ZAC84.89 Billion
% of Total Assets 62.47%
Annual Growth Rate 23.65%
5-Year Change 29.36%
10-Year Change 99.75%
Growth Volatility 31.91

Aspen Pharmacare Holdings Ltd - Net Assets Trend (2003–2025)

This chart illustrates how Aspen Pharmacare Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Aspen Pharmacare Holdings Ltd (2003–2025)

The table below shows the annual net assets of Aspen Pharmacare Holdings Ltd from 2003 to 2025.

Year Net Assets Change
2025-06-30 ZAC84.89 Billion +0.04%
2024-06-30 ZAC84.86 Billion -1.59%
2023-06-30 ZAC86.24 Billion +21.56%
2022-06-30 ZAC70.94 Billion +8.10%
2021-06-30 ZAC65.63 Billion -5.19%
2020-06-30 ZAC69.22 Billion +27.68%
2019-06-30 ZAC54.21 Billion +8.22%
2018-06-30 ZAC50.09 Billion +16.23%
2017-06-30 ZAC43.10 Billion +1.41%
2016-06-30 ZAC42.50 Billion +24.41%
2015-06-30 ZAC34.16 Billion +18.30%
2014-06-30 ZAC28.88 Billion +26.66%
2013-06-30 ZAC22.80 Billion +31.04%
2012-06-30 ZAC17.40 Billion +30.94%
2011-06-30 ZAC13.29 Billion +22.06%
2010-06-30 ZAC10.89 Billion +155.36%
2009-06-30 ZAC4.26 Billion +28.45%
2008-06-30 ZAC3.32 Billion +38.89%
2007-06-30 ZAC2.39 Billion +38.46%
2006-06-30 ZAC1.73 Billion +55.93%
2005-06-30 ZAC1.11 Billion +3.78%
2004-06-30 ZAC1.07 Billion +34.15%
2003-06-30 ZAC794.98 Million --

Equity Component Analysis

This analysis shows how different components contribute to Aspen Pharmacare Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 8947.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Retained Earnings ZAC58.09 Billion 68.43%
Common Stock ZAC1.65 Billion 1.95%
Other Components ZAC25.15 Billion 29.62%
Total Equity ZAC84.89 Billion 100.00%

Aspen Pharmacare Holdings Ltd Competitors by Market Cap

The table below lists competitors of Aspen Pharmacare Holdings Ltd ranked by their market capitalization.

Company Market Cap
Papirfabrikken Invest A/S
CO:PFINV
 		$27.14 Million
KL-Net Corp
KQ:039420
 		$27.14 Million
Ainsworth Game Technology Limited
PINK:AINSF
 		$27.14 Million
SAURASHTRA CEM B ORD (BSE)
NSE:SAURASHCEM
 		$27.14 Million
Shinhan 11th Special Purpose Acquisition Company Co., Ltd.
KQ:452980
 		$27.11 Million
Western Acquisition Ventures Corp
NASDAQ:WAVS
 		$27.11 Million
SKY LIGHT HOLDINGS LTD
F:27L
 		$27.11 Million
Cell MedX Corp
OTCQB:CMXC
 		$27.10 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Aspen Pharmacare Holdings Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 84,861,000,000 to 84,893,000,000, a change of 32,000,000 (0.0%).
  • Net loss of 1,083,000,000 reduced equity.
  • Dividend payments of 1,601,000,000 reduced retained earnings.
  • Share repurchases of 68,000,000 reduced equity.
  • Other comprehensive income decreased equity by 22,445,000,000.
  • Other factors increased equity by 25,229,000,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ZAC-1.08 Billion -1.28%
Dividends Paid ZAC1.60 Billion -1.89%
Share Repurchases ZAC68.00 Million -0.08%
Other Comprehensive Income ZAC-22.45 Billion -26.44%
Other Changes ZAC25.23 Billion +29.72%
Total Change ZAC- 0.04%

Book Value vs Market Value Analysis

This analysis compares Aspen Pharmacare Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 69.35x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 6091.11x to 69.35x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2003-06-30 ZAC2.18 ZAC13259.00 x
2004-06-30 ZAC2.92 ZAC13259.00 x
2005-06-30 ZAC3.16 ZAC13259.00 x
2006-06-30 ZAC4.60 ZAC13259.00 x
2007-06-30 ZAC6.39 ZAC13259.00 x
2008-06-30 ZAC8.53 ZAC13259.00 x
2009-06-30 ZAC10.93 ZAC13259.00 x
2010-06-30 ZAC25.42 ZAC13259.00 x
2011-06-30 ZAC29.11 ZAC13259.00 x
2012-06-30 ZAC38.20 ZAC13259.00 x
2013-06-30 ZAC49.98 ZAC13259.00 x
2014-06-30 ZAC63.29 ZAC13259.00 x
2015-06-30 ZAC74.78 ZAC13259.00 x
2016-06-30 ZAC93.10 ZAC13259.00 x
2017-06-30 ZAC94.43 ZAC13259.00 x
2018-06-30 ZAC109.70 ZAC13259.00 x
2019-06-30 ZAC118.75 ZAC13259.00 x
2020-06-30 ZAC151.62 ZAC13259.00 x
2021-06-30 ZAC143.76 ZAC13259.00 x
2022-06-30 ZAC156.60 ZAC13259.00 x
2023-06-30 ZAC194.14 ZAC13259.00 x
2024-06-30 ZAC191.04 ZAC13259.00 x
2025-06-30 ZAC191.20 ZAC13259.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Aspen Pharmacare Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -1.28%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -2.50%
  • • Asset Turnover: 0.32x
  • • Equity Multiplier: 1.60x
  • Recent ROE (-1.28%) is below the historical average (18.30%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2003 34.71% 14.38% 1.13x 2.14x ZAC194.65 Million
2004 33.34% 16.15% 1.04x 1.98x ZAC248.93 Million
2005 44.63% 17.22% 0.91x 2.83x ZAC383.31 Million
2006 37.52% 18.50% 0.81x 2.51x ZAC468.01 Million
2007 30.21% 17.83% 0.53x 3.17x ZAC480.11 Million
2008 27.04% 17.71% 0.45x 3.39x ZAC544.82 Million
2009 32.36% 16.02% 0.67x 2.99x ZAC935.33 Million
2010 18.27% 19.50% 0.51x 1.83x ZAC895.40 Million
2011 19.57% 20.91% 0.46x 2.03x ZAC1.27 Billion
2012 16.20% 18.47% 0.48x 1.82x ZAC1.08 Billion
2013 15.44% 18.23% 0.43x 1.99x ZAC1.24 Billion
2014 17.34% 16.97% 0.36x 2.86x ZAC2.12 Billion
2015 15.24% 14.40% 0.41x 2.59x ZAC1.79 Billion
2016 10.12% 12.08% 0.34x 2.45x ZAC50.00 Million
2017 11.83% 12.38% 0.35x 2.70x ZAC790.00 Million
2018 12.00% 14.11% 0.32x 2.65x ZAC1.00 Billion
2019 11.92% 16.63% 0.32x 2.26x ZAC1.04 Billion
2020 6.74% 12.07% 0.29x 1.92x ZAC-2.26 Billion
2021 7.32% 12.73% 0.34x 1.67x ZAC-1.76 Billion
2022 9.15% 16.81% 0.35x 1.57x ZAC-606.20 Million
2023 6.06% 12.84% 0.30x 1.56x ZAC-3.40 Billion
2024 5.19% 9.85% 0.32x 1.64x ZAC-4.08 Billion
2025 -1.28% -2.50% 0.32x 1.60x ZAC-9.57 Billion

Industry Comparison

This section compares Aspen Pharmacare Holdings Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $104,016,736
  • Average return on equity (ROE) among peers: 10.18%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Aspen Pharmacare Holdings Ltd (APN) ZAC84.89 Billion 34.71% 0.60x $27.13 Million
CCC (CCC) $52.08 Million 0.87% 0.21x $24.72 Million
Labat Africa Ltd (LAB) $155.95 Million 19.49% 0.79x $44.25K